Immunovant, Inc. — Director's Dealing 2025

Jul 25, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immunovant, Inc. (IMVT)
CIK: 0001764013
Period of Report: 2025-07-23

Reporting Person: Geffner Michael (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-07-23	Common Stock	S	2385	$18.15	Disposed	221825	Direct

Footnotes

F1: On January 17, 2023, the holder was granted 100,000 restricted stock units ("RSUs"), as previously reported on a Form 3 filed on January 16, 2024, of which 6,250 of these RSUs vested on July 17,
2025. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is
mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.